NG9 Stock Overview Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
NeoGenomics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NeoGenomics Historical stock prices Current Share Price US$15.90 52 Week High US$17.30 52 Week Low US$11.80 Beta 1.23 1 Month Change -4.79% 3 Month Change 21.37% 1 Year Change 3.92% 3 Year Change -47.09% 5 Year Change -38.85% Change since IPO 4,576.47%
Recent News & Updates
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2023) Nov 05 Neogenomics, Inc. Revises Full-Year 2024 Guidance
NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 15
NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia Oct 09
NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024 Jul 31
Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2023) Jul 30 See more updates
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2023) Nov 05 Neogenomics, Inc. Revises Full-Year 2024 Guidance
NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 15
NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia Oct 09
NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024 Jul 31
Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2023) Jul 30
NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Jul 10
NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO May 29
NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024 May 03
First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.25 loss in 1Q 2023) May 01 NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics
NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 10
NeoGenomics, Inc., Annual General Meeting, May 23, 2024 Apr 09
Full year 2023 earnings released: US$0.70 loss per share (vs US$1.16 loss in FY 2022) Feb 21
NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024 Feb 21
NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Jan 31
NeoGenomics Laboratories, Inc. to Appeal Ruling Dec 28
NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023 Nov 09
Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.30 loss in 3Q 2022) Nov 07
Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios Oct 25
NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 18
NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023 Aug 10
Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.28 loss in 2Q 2022) Aug 09
NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors Jun 30
NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage Jun 18
NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer Jun 06
NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO May 31
NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023 May 10
First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$1.16 loss per share (vs US$0.07 loss in FY 2021) Feb 24 NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer
Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors Jan 24
The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders Jan 18
Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc Dec 07
NeoGenomics, Inc. Announces Executive Changes Dec 06
Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease Nov 22 NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$0.30 loss per share (vs US$0.17 loss in 3Q 2021) Nov 09
NeoGenomics Appoints David Perez to its Board of Directors Nov 08
NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch Oct 29
NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 14
Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.64 profit in 2Q 2021) Aug 10 NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022 NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index
NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer May 17 Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022 May 10
First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.19 loss in 1Q 2021) Apr 28
High number of new and inexperienced directors Apr 27 NeoGenomics, Inc., Annual General Meeting, Jun 02, 2022 Apr 15
NeoGenomics, Inc. Provides Revenue Guidance for the First Quarter 2022 Mar 30 NeoGenomics, Inc. Announces Management Changes
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Neogenomics, Inc. Provides Earnings Guidance for the Year 2022 Feb 24
Investor sentiment deteriorated over the past week Jan 11
CEO & Director recently bought €462k worth of stock Dec 08
Investor sentiment deteriorated over the past week Dec 04
Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.023 profit in 3Q 2020) Nov 07
Investor sentiment deteriorated over the past week Nov 06
Second quarter 2021 earnings released: EPS US$0.64 (vs US$0.063 loss in 2Q 2020) Aug 08
High number of new and inexperienced directors Aug 04
President of Pharma Services Division recently sold €6.7m worth of stock Jun 05
Independent Director Raymond Hipp has left the company Jun 04
Director Steven Jones has left the company Jun 04
President of Clinical Services Division recently sold €117k worth of stock May 28
Chief Medical Officer has left the company May 10
First quarter 2021 earnings released: US$0.19 loss per share (vs US$0.067 loss in 1Q 2020) May 06
NeoGenomics, Inc. Announces Chief Executive Officer Changes Mar 03
Full year 2020 earnings released: EPS US$0.038 (vs US$0.08 in FY 2019) Feb 25
Revenue beats expectations Feb 25
NeoGenomics, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €48.00 Feb 12
Parexel and Neogenomics, Inc. Announces Strategic Collaboration in Precision Medicine to Improve Study Designs and Accelerate Patient Matching in Oncology Clinical Trials Feb 05
New 90-day high: €46.60 Jan 22
NeoGenomics, Inc. has completed a Follow-on Equity Offering in the amount of $199.999968 million. Jan 08
New 90-day high: €45.20 Dec 23
Independent Director recently sold €974k worth of stock Dec 08
New 90-day high: €40.20 Dec 07
New 90-day high: €38.00 Nov 20
Chairman & CEO recently sold €7.0m worth of stock Nov 19
Third-quarter earnings released: Revenue misses expectations Oct 29
Third quarter earnings released Oct 29
New 90-day high: €37.40 Oct 16
NeoGenomics, Inc. to Report Q3, 2020 Results on Oct 27, 2020 Oct 02
Independent Director recently sold €73k worth of stock Sep 27
New 90-day high - €32.80 Aug 05 Shareholder Returns NG9 DE Healthcare DE Market 7D 1.9% 0.8% 0.3% 1Y 3.9% 18.1% 6.9%
See full shareholder returns
Return vs Market: NG9 underperformed the German Market which returned 7.2% over the past year.
Price Volatility Is NG9's price volatile compared to industry and market? NG9 volatility NG9 Average Weekly Movement 6.9% Healthcare Industry Average Movement 4.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: NG9 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NG9's weekly volatility (7%) has been stable over the past year.
About the Company NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Show more NeoGenomics, Inc. Fundamentals Summary How do NeoGenomics's earnings and revenue compare to its market cap? NG9 fundamental statistics Market cap €2.08b Earnings (TTM ) -€74.73m Revenue (TTM ) €619.26m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NG9 income statement (TTM ) Revenue US$644.12m Cost of Revenue US$363.69m Gross Profit US$280.43m Other Expenses US$358.16m Earnings -US$77.73m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.61 Gross Margin 43.54% Net Profit Margin -12.07% Debt/Equity Ratio 59.5%
How did NG9 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 10:48 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NeoGenomics, Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bruce Jackson Benchmark Company Raymond Myers Benchmark Company Derik de Bruin BofA Global Research
Show 26 more analysts 
